文献速递血栓与止血

无近期肝素或腺病毒载体疫苗暴露的抗PF4免疫血栓形成

Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure.
PubMed 文献 · Blood · 2023-01-01

研究识别了9例无近期肝素暴露或腺病毒载体疫苗接种、但呈现VITT样临床病理特征(血小板减少、血栓形成、D-二聚体显著升高)的患者,其血清在PIPA试验中强阳性、HIPA试验阴性或弱阳性,且新型抗PF4化学发光试验阳性。作者认为,即使无近期肝素或腺病毒载体疫苗暴露,对血小板减少、血栓形成且D-二聚体极高的患者也应考虑血小板活化性VITT样抗PF4抗体。

要点

  • 9例患者无近期肝素或腺病毒载体疫苗暴露,但呈现VITT样临床病理特征。
  • 血栓事件包括动脉性卒中3例和脑静脉窦血栓4例,血小板计数中位最低值49×10^9/L。
  • 9/9血清PIPA聚集时间<10分钟,新型抗PF4化学发光试验阳性(3/9抗PF4/肝素化学发光试验亦阳性)。

核心结论

  • 对血小板减少、血栓形成且D-二聚体极高的患者,即使无近期肝素或腺病毒载体疫苗暴露,也应考虑血小板活化性VITT样抗PF4抗体。

研究设计与样本

  • 研究纳入9例无近期肝素暴露或腺病毒载体疫苗接种、血小板减少伴血栓形成、PF4/多阴离子酶免疫试验强阳性而HIPA试验阴性或弱阳性、PIPA试验强阳性的患者。
  • 对照血清包括2020年前获得的探索性抗PF4抗体阳性但HIPA阴性或弱阳性队列(n=188)。
  • 检测方法包括HemosIL AcuStar HIT-IgG(PF4-H)化学发光试验和一种新型抗PF4化学发光试验。

主要发现

  • 9例患者中动脉性卒中3例、脑静脉窦血栓4例,血小板计数中位最低值49×10^9/L,D-二聚体水平显著升高。
  • 9/9血清PIPA聚集时间<10分钟,新型抗PF4化学发光试验阳性,其中3/9抗PF4/肝素化学发光试验亦阳性。
  • 探索性队列中另发现13份2020年前获得的血清具有VITT样抗PF4抗体。

临床怎么用

  • 作者认为,对血小板减少、血栓形成且D-二聚体极高的患者,即使无近期肝素或腺病毒载体疫苗暴露,也应考虑血小板活化性VITT样抗PF4抗体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies and anti-PF4 antibodies cause heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT), respectively. Diagnostic and treatment considerations differ somewhat between HIT and VITT. We identified patients with thrombocytopenia and thrombosis without proximate heparin exposure or adenovirus-based vaccination who tested strongly positive by PF4/polyanion enzyme-immunoassays and negative/weakly positive by heparin-induced platelet activation (HIPA) test but strongly positive by PF4-induced platelet activation (PIPA) test (ie, VITT-like profile). We tested these patients by a standard chemiluminescence assay that detects anti-PF4/heparin antibodies found in HIT (HemosIL AcuStar HIT-IgG(PF4-H)) as well as a novel chemiluminescence assay for anti-PF4 antibodies found in VITT. Representative control sera included an exploratory anti-PF4 antibody-positive but HIPA-negative/weak cohort obtained before 2020 (n = 188). We identified 9 patients with a clinical-pathological profile of a VITT-like disorder in the absence of proximate heparin or vaccination, with a high frequency of stroke (arterial, n = 3; cerebral venous sinus thrombosis, n = 4), thrombocytopenia (median platelet count nadir, 49 × 109/L), and hypercoagulability (greatly elevated D-dimer levels). VITT-like serological features included strong reactivity by PIPA (aggregation <10 minutes in 9/9 sera) and positive testing in the novel anti-PF4 chemiluminescence assay (3/9 also tested positive in the anti-PF4/heparin chemiluminescence assay). Our exploratory cohort identified 13 additional patient sera obtained before 2020 with VITT-like anti-PF4 antibodies. Platelet-activating VITT-like anti-PF4 antibodies should be considered in patients with thrombocytopenia, thrombosis, and very high D-dimer levels, even without a proximate exposure to heparin or adenovirus vector vaccines.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schönborn L, Esteban O, Wesche J, et al. Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure. Blood. 2023. PMID: 37883798. doi:10.1182/blood.2023022136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。